Wnt5a expression and prognosis in stage II–III colon cancer
Cancer metastases accounts for most cancer deaths. The secreting glycoprotein Wnt5a impairs tumor cell migration and reduces invasiveness and metastasis. High Wnt5a expression in tumor cells is correlated to better outcomes in patients with breast, prostate and epithelial ovarian cancer. We aimed to...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320303843 |
| _version_ | 1818917391558508544 |
|---|---|
| author | Cecilia Margareta Lund Anne Dyhl-Polk Dorte Lisbeth Nielsen Lene Buhl Riis |
| author_facet | Cecilia Margareta Lund Anne Dyhl-Polk Dorte Lisbeth Nielsen Lene Buhl Riis |
| author_sort | Cecilia Margareta Lund |
| collection | DOAJ |
| description | Cancer metastases accounts for most cancer deaths. The secreting glycoprotein Wnt5a impairs tumor cell migration and reduces invasiveness and metastasis. High Wnt5a expression in tumor cells is correlated to better outcomes in patients with breast, prostate and epithelial ovarian cancer. We aimed to investigate the association between the Wnt5a expression and outcomes in patients with colon cancer (CC) stage II/III. We performed a retrospective single-center study evaluating 345 patients with radical resection for primary CC, stage II/III, who started 6 months of adjuvant chemotherapy with 5-FU or capecitabine ± oxaliplatin between 2001 and 2015. Archived formalin-fixed paraffin embedded tumor tissue from resection specimens were stained with Wnt5a antibody using immunohistochemistry. Cytoplasmatic Wnt5a staining was assessed according to intensity and percentage of stained cells. Patients were divided in groups depending on high (n = 230) or low (n = 115) Wnt5a expression. Disease free survival (DFS) and overall survival (OS) were analyzed for the two groups using Kaplan-Meier plots and Long rank test. Patients with Wnt5a-negative tumors had significantly poorer performance status (PS) than patients with high Wnt5a expression (p = 0.046). No significant difference was seen between patients with low and high Wnt5a expression in terms of 5-year DFS (p = 0.517) or 5-year OS (p = 0.415). Poor PS was associated with lower DFS (p = 0.002) and OS (p < 0.001). In conclusion, we found no significant difference in prognosis for patients with stage II/III CC depending on their Wnt5a expression. Patients with Wnt5a-negative tumors had significant poorer PS than patients with higher levels. Poor PS was associated with lower DFS and OS. |
| first_indexed | 2024-12-20T00:33:19Z |
| format | Article |
| id | doaj.art-142b694bfd4047ac8e36cd06ff375cce |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-20T00:33:19Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-142b694bfd4047ac8e36cd06ff375cce2022-12-21T19:59:52ZengElsevierTranslational Oncology1936-52332021-01-01141100892Wnt5a expression and prognosis in stage II–III colon cancerCecilia Margareta Lund0Anne Dyhl-Polk1Dorte Lisbeth Nielsen2Lene Buhl Riis3Department of Medicine, Copenhagen University Hospital, Herlev and Gentofte, Denmark; Copenage, Copenhagen Center for Clinical Age Research, University of Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Denmark; Corresponding author at: Department of Medicine O106, Herlev Hospital, Borgmester Ib Juuls vej 1, 2730 Herlev, Denmark.Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, DenmarkDepartment of Oncology, Copenhagen University Hospital, Herlev and Gentofte, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, DenmarkDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Denmark; Department of Pathology, Copenhagen University Hospital, Herlev and Gentofte, DenmarkCancer metastases accounts for most cancer deaths. The secreting glycoprotein Wnt5a impairs tumor cell migration and reduces invasiveness and metastasis. High Wnt5a expression in tumor cells is correlated to better outcomes in patients with breast, prostate and epithelial ovarian cancer. We aimed to investigate the association between the Wnt5a expression and outcomes in patients with colon cancer (CC) stage II/III. We performed a retrospective single-center study evaluating 345 patients with radical resection for primary CC, stage II/III, who started 6 months of adjuvant chemotherapy with 5-FU or capecitabine ± oxaliplatin between 2001 and 2015. Archived formalin-fixed paraffin embedded tumor tissue from resection specimens were stained with Wnt5a antibody using immunohistochemistry. Cytoplasmatic Wnt5a staining was assessed according to intensity and percentage of stained cells. Patients were divided in groups depending on high (n = 230) or low (n = 115) Wnt5a expression. Disease free survival (DFS) and overall survival (OS) were analyzed for the two groups using Kaplan-Meier plots and Long rank test. Patients with Wnt5a-negative tumors had significantly poorer performance status (PS) than patients with high Wnt5a expression (p = 0.046). No significant difference was seen between patients with low and high Wnt5a expression in terms of 5-year DFS (p = 0.517) or 5-year OS (p = 0.415). Poor PS was associated with lower DFS (p = 0.002) and OS (p < 0.001). In conclusion, we found no significant difference in prognosis for patients with stage II/III CC depending on their Wnt5a expression. Patients with Wnt5a-negative tumors had significant poorer PS than patients with higher levels. Poor PS was associated with lower DFS and OS.http://www.sciencedirect.com/science/article/pii/S1936523320303843Colon cancerDisease free survivalOverall survivalPerformance statusWnt5a |
| spellingShingle | Cecilia Margareta Lund Anne Dyhl-Polk Dorte Lisbeth Nielsen Lene Buhl Riis Wnt5a expression and prognosis in stage II–III colon cancer Translational Oncology Colon cancer Disease free survival Overall survival Performance status Wnt5a |
| title | Wnt5a expression and prognosis in stage II–III colon cancer |
| title_full | Wnt5a expression and prognosis in stage II–III colon cancer |
| title_fullStr | Wnt5a expression and prognosis in stage II–III colon cancer |
| title_full_unstemmed | Wnt5a expression and prognosis in stage II–III colon cancer |
| title_short | Wnt5a expression and prognosis in stage II–III colon cancer |
| title_sort | wnt5a expression and prognosis in stage ii iii colon cancer |
| topic | Colon cancer Disease free survival Overall survival Performance status Wnt5a |
| url | http://www.sciencedirect.com/science/article/pii/S1936523320303843 |
| work_keys_str_mv | AT ceciliamargaretalund wnt5aexpressionandprognosisinstageiiiiicoloncancer AT annedyhlpolk wnt5aexpressionandprognosisinstageiiiiicoloncancer AT dortelisbethnielsen wnt5aexpressionandprognosisinstageiiiiicoloncancer AT lenebuhlriis wnt5aexpressionandprognosisinstageiiiiicoloncancer |